TY - JOUR
T1 - Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy
AU - van Duijvenvoorde, Maurice
AU - Derks, Sarah
AU - Bahce, Idris
AU - Leemans, C René
AU - van de Ven, Rieneke
AU - Fransen, Marieke F
N1 - Publisher Copyright: © 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc
PY - 2022
Y1 - 2022
N2 - Immunotherapy with immune checkpoint inhibitors (ICI) has improved treatment outcomes in many cancer types and has focused attention on cancer immunity and the role of the tumor microenvironment (TME). Studies into efficacy of immunotherapy and TME are generally restricted to tumors in one anatomical location, while the histological type may have substantial influence on the contexture of the TME, perhaps more so than anatomical location, and subsequently to the response to immunotherapy. This review aims to focus on the TME in ICI-treated tumors of the same histological type, namely carcinogen-induced squamous cell carcinoma developing within the aerodigestive tract, at three locations, i.e. head and neck (HNSCC), esophagus (ESCC) and lung (LUSC).
AB - Immunotherapy with immune checkpoint inhibitors (ICI) has improved treatment outcomes in many cancer types and has focused attention on cancer immunity and the role of the tumor microenvironment (TME). Studies into efficacy of immunotherapy and TME are generally restricted to tumors in one anatomical location, while the histological type may have substantial influence on the contexture of the TME, perhaps more so than anatomical location, and subsequently to the response to immunotherapy. This review aims to focus on the TME in ICI-treated tumors of the same histological type, namely carcinogen-induced squamous cell carcinoma developing within the aerodigestive tract, at three locations, i.e. head and neck (HNSCC), esophagus (ESCC) and lung (LUSC).
UR - http://www.scopus.com/inward/record.url?scp=85123555093&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/cti2.1363
DO - https://doi.org/10.1002/cti2.1363
M3 - Review article
C2 - 35035956
SN - 2050-0068
VL - 11
SP - e1363
JO - Clinical & translational immunology
JF - Clinical & translational immunology
IS - 1
M1 - e1363
ER -